Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Analyst Ratings
Strong Buy
10 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BEAM Stock 12 Month Forecast
Average Price Target
$42.00
▲(24.67% Upside)
| Highest Price Target$80.00 | Average Price Target$42.00 | Lowest Price Target$21.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
Buy
―
Reiterated
01/12/26
We view Beam’s update positively, as it indicates the company has clear line of sight into the data packages necessary to support BLAs for risto-cel and BEAM-302. Both programs’ acceptance into the FDA’s CDRP could also aide in accelerating the clinical development and regulatory review process, in our view. In addition, the company has extended its cash runway by more than a year compared to its previous estimate, relieving some of the financial pressure on the stock. We expect the near-term BEAM-302 data update and disclosure of the pivotal development pathway, including the use of 12-month AAT biomarkers as a surrogate endpoint for accelerated approval, to be key catalysts for the stock.
Bank of America Securities
$45
Buy
33.57%
Upside
Reiterated
01/12/26
UBS
$28
Hold
-16.89%
Downside
Initiated
01/06/26
Wells Fargo
$100→$70
Buy
107.78%
Upside
Reiterated
01/05/26
Evercore ISI
$35
Buy
3.89%
Upside
Reiterated
12/23/25
H.C. Wainwright
$80
Buy
137.46%
Upside
Reiterated
12/09/25
Wedbush
$57
Buy
69.19%
Upside
Reiterated
12/09/25
JonesTrading
$25→$35
Buy
3.89%
Upside
Reiterated
12/08/25
Bernstein
$32
Buy
-5.02%
Downside
Reiterated
12/01/25
Barclays
$21
Hold
-37.67%
Downside
Reiterated
11/05/25
Clear Street
$34→$37
Buy
9.82%
Upside
Reiterated
11/04/25
RBC Capital
$22
Hold
-34.70%
Downside
Reiterated
11/04/25
Jefferies
$41
Buy
21.70%
Upside
Initiated
10/09/25
Leerink Partners
Buy
―
Reiterated
09/03/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
Buy
―
Reiterated
01/12/26
We view Beam’s update positively, as it indicates the company has clear line of sight into the data packages necessary to support BLAs for risto-cel and BEAM-302. Both programs’ acceptance into the FDA’s CDRP could also aide in accelerating the clinical development and regulatory review process, in our view. In addition, the company has extended its cash runway by more than a year compared to its previous estimate, relieving some of the financial pressure on the stock. We expect the near-term BEAM-302 data update and disclosure of the pivotal development pathway, including the use of 12-month AAT biomarkers as a surrogate endpoint for accelerated approval, to be key catalysts for the stock.
Bank of America Securities
$45
Buy
33.57%
Upside
Reiterated
01/12/26
UBS
$28
Hold
-16.89%
Downside
Initiated
01/06/26
Wells Fargo
$100→$70
Buy
107.78%
Upside
Reiterated
01/05/26
Evercore ISI
$35
Buy
3.89%
Upside
Reiterated
12/23/25
H.C. Wainwright
$80
Buy
137.46%
Upside
Reiterated
12/09/25
Wedbush
$57
Buy
69.19%
Upside
Reiterated
12/09/25
JonesTrading
$25→$35
Buy
3.89%
Upside
Reiterated
12/08/25
Bernstein
$32
Buy
-5.02%
Downside
Reiterated
12/01/25
Barclays
$21
Hold
-37.67%
Downside
Reiterated
11/05/25
Clear Street
$34→$37
Buy
9.82%
Upside
Reiterated
11/04/25
RBC Capital
$22
Hold
-34.70%
Downside
Reiterated
11/04/25
Jefferies
$41
Buy
21.70%
Upside
Initiated
10/09/25
Leerink Partners
Buy
―
Reiterated
09/03/25
Best Analysts Covering Beam Therapeutics
3 Months
xxx
Success Rate
12/15 ratings generated profit
Average Return
+9.57%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +9.57% per trade.
1 Year
Success Rate
11/15 ratings generated profit
Average Return
+43.51%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +43.51% per trade.
2 Years
xxx
Success Rate
14/15 ratings generated profit
Average Return
+28.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +28.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BEAM Analyst Recommendation Trends
Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
13
15
12
12
11
Buy
4
6
6
10
11
Hold
3
3
3
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
24
21
24
25
Each month's total comprises the sum of three months' worth of ratings.
BEAM Financial Forecast
BEAM Stock Forecast FAQ
What is BEAM’s average 12-month price target, according to analysts?
Based on analyst ratings, Beam Therapeutics’s 12-month average price target is 42.00.
What is BEAM’s upside potential, based on the analysts’ average price target?
Beam Therapeutics has 24.67% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BEAM a Buy, Sell or Hold?
Beam Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 3 hold ratings and 0 sell ratings.
What is Beam Therapeutics’s price target?
The average price target for Beam Therapeutics is 42.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $21.00. The average price target represents 24.67% Increase from the current price of $33.69.
The highest analyst price target is $80.00 ,the lowest forecast is $21.00. The average price target represents 24.67% Increase from the current price of $33.69.
What do analysts say about Beam Therapeutics?
Beam Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of BEAM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.